Althaf Singhawansa

Mr. Althaf Singhawansa

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2026 in Nature Cancer
Verified
Journal Article
Open access
PDF file
YZYong Zeng
Yong Zeng
DADor D. Abelman
Dor D. Abelman
ASAlthaf Singhawansa
Althaf Singhawansa
NCNicholas Cheng
Nicholas Cheng
YFYuanchang Fang
Yuanchang Fang
HHHousheng Hansen He
Housheng Hansen He
Cell-free DNA analysis via methylation and fragmentation profiling has advanced minimally invasive cancer detection; however, broader application has been limited by small cohorts and inconsistent data processing. Here we collated 1,074 cfMeDIP-seq profiles across 9 studies, comprising cancer samples from 11 cancer types, carriers of Li-Fraumeni syndrome and healthy controls. We developed a uniform computational workflow to mitigate technical and biological confounders across cohorts. This analysis identified 14,202 pancancer differentially methylated regions for cancer detection, along with cancer-specific markers for subtype monitoring. Fragmentomic profiling revealed distinguishing differences in 5′ end motifs, fragment lengths and nucleosome footprints across cancers. Integrating methylome and fragmentome features enhanced cancer detection and classification. Validation in 220 independent samples, including 3 cancer types absent from the primary dataset, confirmed the robustness of our findings. Altogether, this work provides a pancancer cell-free DNA resource of 1,294 samples to support future methylome and fragmentome studies.

10 June 2026 in Cancer Research
Verified
Journal Article
Open access
SMSasha C. Main
Sasha C. Main
MEMitchell J. Elliott
Mitchell J. Elliott
ASAlthaf Singhawansa
Althaf Singhawansa
JZJinfeng Zou
Jinfeng Zou
YZYong Zeng
Yong Zeng
DCDavid W. Cescon
David W. Cescon
The management of metastatic breast cancer (mBC) relies on tissue-based immunohistochemical subtypes. However, biopsies are invasive, may not capture metastatic heterogeneity, and subtypes can change over time under treatment pressure. Here, we developed cell-free DNA (cfDNA) methylation signatures for minimally invasive BC detection, distinction, and estrogen receptor (ER) status classification. Peripheral blood plasma methylomes were analyzed from 79 patients with mBC spanning ER+/HER2- (n=45), HER2+ (n=13), and triple-negative BC (TNBC; n=21). To derive tissue-informed BC and ER-specific features, public 450K methylation array data (n=9730) were leveraged, and features were selected using generalized linear models via elastic net regularization (GLMnet) with cross-validation. The tissue-informed features were translated to cell-free methylated DNA immunoprecipitation and sequencing (cfMeDIP-seq), and the final signatures were validated across a compendium of cfMeDIP-seq profiles (n=713) spanning over ten cancer types. Across training, validation, and external test cohorts, the signatures demonstrated high accuracy for BC detection versus controls, distinction from multiple other malignancies, and ER status classification. Performance generalized across independent cfMeDIP-seq cohorts and reflected tumor fraction. The sensitivity was reduced in samples with low tumor fractions and bone-only disease, while remaining informative for typical tumor fractions observed in the metastatic setting. Promoter-proximal signature regions provided biological insight into tumor phenotypes. This tissue-anchored, platform-translatable framework demonstrates the feasibility of accurate, reproducible cfDNA methylation-based molecular classification in mBC.



2 September 2026
Verified
Other
Open access
SMSasha C. Main
Sasha C. Main
MEMitchell J. Elliott
Mitchell J. Elliott
ASAlthaf Singhawansa
Althaf Singhawansa
JZJinfeng Zou
Jinfeng Zou
YZYong Zeng
Yong Zeng
DCDavid W. Cescon
David W. Cescon
Supplementary Tables 1-9 from Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer

Verified
Journal Article
Open access
PDF file
JLJanice Li
Janice Li
DCDangxiao Cheng
Dangxiao Cheng
LZLuna J. Zhan
Luna J. Zhan
DSDanielle Benedict Sacdalan
Danielle Benedict Sacdalan
SHSami Ul Haq
Sami Ul Haq
BLBenjamin H Lok
Benjamin H Lok
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma characterized by poor survival. Despite a high tumor mutation burden, biomarker discovery in SCLC remains challenging due to rapid tumor plasticity and limited tissue availability, highlighting the promise of liquid biopsy-based approaches. Epigenetic dysregulation of DNA 5-hydroxymethylcytosine (5hmC) has emerged as a cancer hallmark. However, its role in SCLC remains largely unexplored. Here, we characterized the cell-free DNA (cfDNA) 5hmC landscape in SCLC and evaluated its potential applications. We profiled the cell-free hydroxymethylomes of 107 pre-treatment SCLC patients and 53 matched controls using the 5hmC selective chemical labeling (5hmC-Seal) assay. SCLC displayed higher global 5hmC levels and distinct enrichment at neurodevelopmental and synaptic pathways, consistent with the neuroendocrine identity of SCLC. Concordance between plasma and matched circulating tumor cell patient-derived xenograft (CDX) demonstrated that cfDNA 5hmC reflects tumor epigenetic states and correlates with transcriptomic-derived molecular subtypes. Elevated SCLC-specific 5hmC levels and extensive stage (ES) disease were associated with inferior survival, with ES disease showing enrichment of pathways linked to cellular plasticity and neurodevelopment. Together, these findings indicate that cfDNA 5hmC profiling has potential as a biologically informative and clinically relevant biomarker in SCLC, with possible applications in tumor subtyping and risk stratification.